Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis

NCT00694629 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT00694629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00694629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
December 31, 2013
Enrollment
334 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis